Search Results
Your search for The ASCO,The ASCO matches 21130 pages
Showing 11851 - 11900FDA Approves sBLA Updating Nivolumab Dosing Schedule Across Indications
On March 6, Bristol-Myers Squibb announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the nivolumab (Opdivo) dosing schedule to include 480 mg infused every 4 weeks for a majority of approved indications. This approval will ...
FDA Authorizes Direct-to-Consumer Test That Reports Three Mutations in the BRCA1/BRCA2 Breast Cancer Genes
Today, the U.S. Food and Drug Administration (FDA) authorized the Personal Genome Service Genetic Health Risk (GHR) Report for BRCA1/BRCA2 (Selected Variants). It is the first direct-to-consumer (DTC) test to report on three specific BRCA1/BRCA2 breast cancer gene mutations that are most common in...
Multitargeted Tyrosine Kinase Inhibitor Shows Activity in Small Cell Carcinoma of the Ovary
An multitargeted tyrosine kinase inhibitor used to treat leukemia has shown promise against a rare and aggressive type of ovarian cancer—small cell carcinoma of the ovary hypercalcemic type (SCCOHT)—that strikes young women and girls, according to a study led by the Translational...
E. John Wherry, PhD, Awarded SU2C Funding to Lead Investigation of Gynecologic Cancer Therapies
E. John Wherry, PhD, a cancer and immunology researcher at the Perelman School of Medicine at the University of Pennsylvania and one of the most highly cited investigators in his field, has been awarded a “Convergence 2.0” research grant by Stand Up to Cancer (SU2C) to investigate immune system...
Statement on Biosimilars in Oncology Aims to Educate ASCO Members
Biosimilars have rapidly proliferated in the cancer care landscape, leaving many providers unclear about the full impact these products will have on the care they deliver to patients. “American Society of Clinical Oncology Statement: Biosimilars in Oncology,” published in the Journal of Clinical...
Texas Society of Clinical Oncology Makes Investment in Young Investigators
The Texas Society of Clinical Oncology (TxSCO) is one of the newest supporters of the Conquer Cancer Foundation’s Young Investigator Award (YIA) program. A state affiliate of ASCO, TxSCO currently has more than 600 members who represent a diverse array of oncology health providers in Texas. “We are ...
Second Brazilian Practice Achieves QOPI® Certification
Clinica AMO has become the second practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program, LLC, and the sixth practice internationally to receive this accreditation. The practice, located in Salvador, Bahia, on Brazil’s east coast, ...
ASCO, NCCN Provide Guidance on Understanding and Managing Immunotherapy Side Effects
Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body’s immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into...
Cognitive Decline Prevalent Among Elderly Patients With Hematologic Cancers
A sizable percentage of elderly patients with blood-related cancers such as leukemia and multiple myeloma are apt to show signs of diminished cognitive functioning—a decline that may impact their survival—a new study by investigators at Dana-Farber Cancer Institute and Brigham and...
Called to Lead: Tara O. Henderson, MD, MPH, Selected for Presidential Leadership Scholars Program
ASCO congratulates pediatric oncologist Tara O. Henderson, MD, MPH, on being selected for the 2018 Presidential Leadership Scholars (PLS) program. This highly competitive and prestigious national program was created to help individuals from many professional backgrounds develop the practical...
Alex Huang, MD, PhD, Receives $450,000 From Pediatric Cancer Research Foundation
Cancer researcher Alex Huang MD, PhD, has received a $450,000 Basic Science grant from the Pediatric Cancer Research Foundation to study targeted approaches for effectively eliminating metastatic osteosarcoma. Dr. Huang is Professor of Pediatrics at Case Western Reserve University School of...
The Skin Cancer Foundation Announces Office Relocation
The Skin Cancer Foundation, the leading nonprofit organization for public and professional skin cancer education, recently moved to a new office space at 205 Lexington Avenue in midtown Manhattan. The new office will allow the Foundation to grow its staff as it develops new patient support programs ...
Why Right-to-Try Laws Are Dangerous
Why wouldn’t you support a patient with a terminal illness the “right to try” any therapy that may save his or her life? The answer to this question—one engulfed in a political debate in Congress—seems simple. It is not. [Editor’s Note: On May 30, 2018, the President signed into law the Trickett...
Genomic Analyses Highlight Need for Precision Therapies That Target Pediatric Cancers
Researchers have determined that children and adults with cancer often have different mutated genes driving their disease, which suggests they would likely benefit from different therapies. The finding, from a collaborative study led by St. Jude Children’s Research Hospital and published by...
FDA Grants Fast Track Designation to Pamrevlumab in Locally Advanced Unresectable Pancreatic Cancer
On March 1, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for the anti–connective tissue growth factor (CTGF) antibody pamrevlumab for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the phase II clinical...
Body Mass Index and Outcomes With Targeted Therapy, Immunotherapy, or Chemotherapy in Metastatic Melanoma
In a study reported in The Lancet Oncology, McQuade et al found that obesity was associated with improved outcomes in treatment of metastatic melanoma with targeted therapy or immunotherapy—but not chemotherapy—with a survival benefit appearing to be restricted to obese male patients....
Nut Consumption in Patients With Stage III Colon Cancer
People with stage III colon cancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don’t, according to findings published by Fadelu et al in the Journal of Clinical Oncology. Findings The study followed 826 participants in the CALGB...
GC4419 Receives FDA Breakthrough Therapy Designation for the Reduction of Severe Oral Mucositis
On February 28, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to GC4419, a highly selective and potent small molecule dismutase mimetic, for the reduction of the duration, incidence, and severity of severe oral mucositis induced by radiation therapy with...
FDA Accepts BLA for Calaspargase Pegol in Acute Lymphoblastic Leukemia
On February 28, Shire announced that the U.S. Food and Drug Administration (FDA) accepted the company’s biologics license application (BLA) for calaspargase pegol (Cal-PEG; SHP663). The investigational-stage compound is being reviewed as a component of a multiagent chemotherapeutic regimen...
New NCCN Guidelines Aim to Encourage More People Living With HIV and Cancer to Receive Appropriate Cancer Treatment
The National Comprehensive Cancer Network® (NCCN) has released new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) intended to help make sure people living with human immunodeficiency virus (HIV) who are diagnosed with cancer receive safe, necessary treatment. According to ...
Experiences With Radiation Therapy Better Than Expected for Most Patients With Breast Cancer
A new study reveals that many patients with breast cancer have misconceptions and fears about radiation therapy, but their actual experiences with this treatment modality are better than they expected. In the study published by Shaverdian et al in Cancer, most patients agreed that their initial...
FDA Approves Abemaciclib as Initial Therapy for Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
On February 26, the U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative advanced...
FDA Grants Orphan Drug Designation to YS-ON-001 for the Treatment of Pancreatic Cancer
On February 26, Yisheng Biopharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to its lead immuno-oncology candidate, YS-ON-001, for the treatment of pancreatic cancer. YS-ON-001 is a clinical-stage immuno-oncology biologic product...
ASCO Clinical Practice Guideline: Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy
As reported in the Journal of Clinical Oncology by Julie R. Brahmer, MD, of the Johns Hopkins Kimmel Cancer Center, and colleagues, ASCO has released a clinical practice guideline on management of immune-related adverse events in patients receiving immune checkpoint inhibitor therapy. To develop...
Study Shows Need for Early Supportive Care in Patients Diagnosed With Uveal Melanoma
In a study published by Williamson et al in JAMA Ophthalmology, University of California, Los Angeles, (UCLA) researchers found that nearly all patients diagnosed with uveal melanoma had a number of unmet psychological and health information needs, particularly during the first 3 months after their ...
Five Novel Genetic Changes Linked to Pancreatic Cancer Risk
In what is believed to be the largest pancreatic cancer genome-wide association study to date, researchers at the Johns Hopkins Kimmel Cancer Center, the National Cancer Institute, and collaborators from over 80 other institutions worldwide discovered changes to 5 new regions in the human genome...
New Edition of Hematology: Basic Principles and Practice Now Available
THE 7th AND LATEST EDITION of Hematology: Basic Principles and Practice has been published by Elsevier. This authoritative reference in the field of hematology delivers expert scientific content and clinical guidance to enhance problem-solving skills and make optimal use of the newest diagnostic...
Medical and Radiation Oncologists Now Able to Meet All Federal Reporting Requirements Through QOPI Reporting Registry
ASCO AND the American Society for Radiation Oncology (ASTRO) have launched their new, joint platform for quality reporting, making it easier for oncologists to comply with federal government reporting requirements in 2018. The new QOPI® Reporting Registry, a Qualified Clinical Data Registry (QCDR), ...
ASCO Answers Guide to Cancer Survivorship
THIS SURVIVORSHIP resource will inform your patients and their caregivers about the importance of seeking follow-up care, addressing recurrence concerns, and managing long-term and late effects. The guide also includes: Blank treatment summary and survivorship care form List of questions to ask ...
ASCO in Action’s New Podcast Series Addresses Critical Cancer Policy and Practice Issues
IN JANUARY 2018, ASCO launched the ASCO in Action Podcast, a new podcast series hosted by ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO. This series features thought leaders and experts in oncology discussing the most pressing policy and practice issues impacting the cancer care...
Team Wellness: Reflections From Front-Line Clinical Teams
In May 2017, I started to reflect on my own personal views of wellness and the importance of the team. Since that time, I have been fortunate to speak with members of front-line clinical teams from four different practices: Eric Tetzlaff, MSH, PA-C, and Michael Hall, MD, MS, of Fox Chase Cancer...
USPSTF Recommends Against Screening for Ovarian Cancer in Asymptomatic Women
THE U.S. PREVENTIVE Services Task Force (USPSTF) recently published a final recommendation statement and evidence summary on screening for ovarian cancer. Based on its review of the evidence, the USPSTF recommends against screening for ovarian cancer in women who do not have any signs or symptoms...
U.S. Incidence and Projected Rise of Merkel Cell Carcinoma
The number of U.S. cases of Merkel cell carcinoma is rising about six times faster than most other cancers, and at nearly twice the rate of melanoma. Paulson et al reported these findings in The Journal of the American Academy of Dermatology, which are based on research conducted at the University...
FDA Accepts NDA, Grants Priority Review for Ivosidenib in Relapsed or Refractory IDH1-Mutated AML
On February 15, the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for ivosidenib (AG-120) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation. The NDA was granted Priority Review...
UCLA Scientists Receive NIH Research Grant to Advance Adoption of Focal Laser Therapy for Prostate Cancer
UNIVERSITY OF CALIFORNIA (UCLA) researchers Leonard Marks, MD, and Shyam Natarajan, PhD, will lead a $3.1 million research project grant awarded by the National Institutes of Health to advance the adoption of a promising new technology to treat men with prostate cancer. By helping to increase the ...
Priyanka Sharma, MD, Appointed Vice Chair of SWOG Breast Committee
PRIYANKA SHARMA, MD, a breast cancer medical oncologist at The University of Kansas Cancer Center, has been named Vice Chair of SWOG’s Breast Committee. SWOG, formerly the Southwest Oncology Group, is a global cancer research community that designs and conducts publicly funded clinical trials. It ...
New Head of GI Medical Oncology at Perlmutter Cancer Center
PAUL E. OBSERSTEIN, MD, will join New York University (NYU) Langone Health and its Perlmutter Cancer Center as Director of Gastrointestinal Medical Oncology and Assistant Director of the institution’s recently established Pancreatic Cancer Center. Prior to his new post at NYU Langone, Dr....
Human Genome Project Receives Thai Annual Award
THE HUMAN GENOME PROJECT has been awarded the 2017 Prince Mahidol Award, a Thai Royal Family annual award for groundbreaking advances in the fields of medicine and public health. The award was received on behalf of the project by Eric Green, MD, PhD, Director of the National Human Genome Research...
Madhav V. Dhodapkar, MBBS, Named Director of New Center for Cancer Immunology at Winship Cancer Institute
MADHAV V. DHODAPKAR, MBBS, a world-renowned expert in cancer immunology and translational immunotherapy, joined Winship Cancer Institute of Emory University as Director of the new Winship Center for Cancer Immunology. He has been appointed as the Anise McDaniel Brock Chair, Georgia Research...
FDA Approves Abiraterone Acetate Plus Prednisone for High‑Risk Metastatic Castration-Sensitive Prostate Cancer
ON FEBRUARY 7, 2018, the U.S. Food and Drug Administration (FDA) approved abiraterone acetate (Zytiga) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer. The FDA initially approved abiraterone acetate with prednisone in 2011 for patients with...
Why Palliative Care Isn’t Just for Older Patients With Cancer
It is well established that adolescents and young adults (AYAs) with cancer—defined by the National Cancer Institute as those between the ages of 15 and 39 years—have not reaped a comparable survival benefit as either younger or older adult cancer survivors over the past 4 decades, despite...
Results From Phase III ARROW Study of Once-Weekly Carfilzomib in Relapsed or Refractory Multiple Myeloma
TOPLINE RESULTS of the phase III ARROW trial (ClinicalTrials.gov identifier NCT02412878) were recently announced by Amgen. The study showed carfilzomib (Kyprolis) administered once weekly at 70 mg/m2 with dexamethasone allowed patients with relapsed or refractory multiple myeloma to live 3.6 months ...
Retrospective Analysis Suggests Obesity Associated With Longer Survival for Men With Metastatic Melanoma
OBESE PATIENTS with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal body mass index (BMI), according to a study published in The Lancet Oncology of 1,918 patients in 6 independent clinical cohorts.1 This effect—referred to as ...
ASCO Clinical Practice Guideline Update: Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
AS REPORTED in the Journal of Clinical Oncology by Arlene A. Forastiere, MD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and colleagues, ASCO has issued a clinical practice guideline update on the use of larynx-preservation strategies in the treatment of laryngeal cancer.1...
Does Treatment With Tumor-Treating Fields Plus Temozolomide Influence Quality of Life in Patients With Newly Diagnosed Glioblastoma?
A DETAILED quality-of-life analysis of the phase III EF-14 trial of tumor-treating fields (Optune) in combination with temozolomide for the treatment of newly diagnosed glioblastoma was published by Taphoorn et al in JAMA Oncology.1 This secondary endpoint analysis showed the addition of...
CancerCare Raises Nearly $665,000 to Support Patients With Cancer Affected by Hurricanes
SINCE SEPTEMBER 2017, the national nonprofit organization CancerCare has raised nearly $665,000 to provide direct financial assistance for people with cancer who have been impacted by hurricanes. The majority of this support has been allocated to people with cancer in Puerto Rico, many of whom are...
World Cancer Day Addresses Global Disparities in Cancer Care
FEBRUARY 4 was World Cancer Day, which raises awareness for the millions of people worldwide facing unequal access to cancer detection, treatment, and care services. Oncology leaders, health-care professionals, and supporters across the world are pushing for urgent action to reduce the rate of...
Combining Ultrasound Imaging With Alpha-Fetoprotein Test May Boost Detection of Hepatocellular Carcinoma
Combining ultrasound imaging with a blood test for high alpha fetoprotein levels may improve detection of early-stage liver cancer by as much as 40%, researchers at UT Southwestern’s Simmons Cancer Center found. Their findings were presented by Tzartzeva et al in Gastroenterology....
Family History Increases Breast Cancer Risk, Even in Women Aged 65 and Older
A family history of breast cancer continues to significantly increase chances of developing invasive breast tumors in women aged 65 years and older, according to research published by Braithwaite et al in JAMA Internal Medicine. The findings could impact mammography screening decisions later in...
David Baraghoshi, on Colorectal Cancer and Cardiovascular Disease Risk
David Baraghoshi, of the Huntsman Cancer Institute at the University of Utah, discusses an assessment of cardiovascular risk more than 10 years after diagnosis for colorectal cancer survivors compared with a cancer-free general population cohort (Abstract 113).
